Analysts Set Centessa Pharmaceuticals plc (NASDAQ:CNTA) Target Price at $25.83

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has earned an average recommendation of “Buy” from the six brokerages that are currently covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $25.83.

CNTA has been the topic of a number of research reports. BMO Capital Markets raised their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, September 16th. Jefferies Financial Group upped their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Guggenheim raised their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. B. Riley started coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They issued a “buy” rating and a $33.00 price objective for the company. Finally, Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $11.00 to $26.00 in a report on Thursday, September 19th.

Insider Buying and Selling

In related news, CTO Tia L. Bush sold 17,813 shares of Centessa Pharmaceuticals stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $18.00, for a total value of $320,634.00. Following the transaction, the chief technology officer now owns 147,615 shares of the company’s stock, valued at approximately $2,657,070. This trade represents a 10.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Saurabh Saha sold 87,496 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $18.46, for a total transaction of $1,615,176.16. Following the sale, the chief executive officer now owns 575,661 shares in the company, valued at $10,626,702.06. This represents a 13.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 368,023 shares of company stock valued at $6,335,574 over the last 90 days. 11.59% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CNTA. Mirae Asset Global Investments Co. Ltd. grew its position in Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after acquiring an additional 826 shares in the last quarter. GAMMA Investing LLC increased its stake in Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after acquiring an additional 1,509 shares during the period. Quarry LP raised its stake in shares of Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after purchasing an additional 3,108 shares in the last quarter. Sandia Investment Management LP acquired a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter valued at about $90,000. Finally, Fred Alger Management LLC acquired a new stake in Centessa Pharmaceuticals during the second quarter valued at approximately $99,000. 82.01% of the stock is owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Stock Down 3.5 %

Centessa Pharmaceuticals stock opened at $16.35 on Friday. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of -10.69 and a beta of 1.52. Centessa Pharmaceuticals has a fifty-two week low of $6.65 and a fifty-two week high of $18.97. The stock’s fifty day moving average is $16.73 and its two-hundred day moving average is $13.92. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. Analysts predict that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.